Diaceutics PLC PDMR Shareholding/Share Incentive Plan
October 02 2024 - 1:00AM
RNS Regulatory News
RNS Number : 5549G
Diaceutics PLC
02 October 2024
Diaceutics PLC
PDMR Shareholding/Share Incentive
Plan
Belfast and London, 2 October 2024
- Diaceutics
PLC (AIM: DXRX), a leading technology and
solutions provider to the pharma and biotech industry, has
been notified that on 30 September 2024, Global
Shares Trustees (UK) Limited (the "UK Trust") and
Zedra Trust Company (Guernsey) Limited, the trustees of the
Global Diaceutics plc 2020 Employee Benefit
Trust, have purchased ordinary shares of
£0.002 in the capital of the Company ("Shares") on behalf of
Susanne Munksted, Jordan Clark, Nick Roberts and Jillian Beggs
(PDMRs), in respect of their purchase of Shares pursuant to the
Company's UK and Global Share Incentive Plan ("the SIP Schemes")
for employees. These purchases will be made each
month until further notice.
In accordance with the SIP Schemes, the Company
has matched these purchases with a matched share award over an
equivalent number of Shares purchased by the employee, in the
proportion of 1:1.
Enquiries:
|
Diaceutics
PLC
|
Tel: +44 (0)28 9040
6500
|
|
Nick Roberts, Chief Financial
Officer
|
investorrelations@diaceutics.com
|
|
|
|
|
Canaccord
Genuity Limited (Nomad & Broker)
|
Tel: +44 (0)20 7253
8000
|
|
Simon Bridges, Andrew Potts, Harry
Rees
|
|
|
|
|
|
Alma Strategic
Communications
|
Tel: +44(0)20 3405
0205
|
|
Caroline Forde, Kinvara Verdon
|
diaceutics@almastrategic.com
|
About Diaceutics
At Diaceutics we believe that every
patient should get the opportunity to receive the right test and
the right therapy to positively impact their disease
outcome.
We provide the world's leading
pharma and biotech companies with an end-to-end commercialisation
solution for precision medicines through data analytics, scientific
and advisory services enabled by our platform DXRX - The
Diagnostics Network ®.
|
Notification of a Transaction pursuant to Article 19(1) of
Regulation (EU) No. 596/2014
|
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a.
|
Name
|
Susanne Munksted
|
|
2
|
Reason for notification
|
|
|
a.
|
Position/Status
|
Chief Precision Medicine Officer
|
|
b.
|
Initial notification/
Amendment
|
Initial
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a.
|
Name
|
Diaceutics PLC
|
|
b.
|
LEI
|
213800VEWQBB39ZB8J81
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a.
|
Description of the financial
instrument, type of instrument
Identification Code
|
Ordinary shares of
£0.002 each
ISIN:
GB00BJQTGV64
|
|
b.
|
Nature of the transaction
|
Ongoing non-discretionary purchase
of Shares matched by the grant of conditional share award over
Shares under the Global Share Incentive Plan ("SIP")
|
|
c.
|
Price(s) and volume(s)
|
|
Share purchase:
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
134 p
|
108
|
|
|
|
Conditional share award:
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
Nil
|
108
|
|
|
|
|
e.
|
Date of the transaction
|
Share purchase and Conditional share
award: 30 September 2024
|
|
f.
|
Place of the transaction
|
Share Purchase: AIM Market of the
London Stock Exchange
Conditional share award:
Off-Market
|
|
|
|
|
|
|
|
| |
|
Notification of a Transaction pursuant to Article 19(1) of
Regulation (EU) No. 596/2014
|
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a.
|
Name
|
Jordan Clark
|
|
2
|
Reason for notification
|
|
|
a.
|
Position/Status
|
Chief Data Officer
|
|
b.
|
Initial notification/
Amendment
|
Initial
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a.
|
Name
|
Diaceutics PLC
|
|
b.
|
LEI
|
213800VEWQBB39ZB8J81
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a.
|
Description of the financial
instrument, type of instrument
Identification Code
|
Ordinary shares of
£0.002 each
ISIN:
GB00BJQTGV64
|
|
b.
|
Nature of the transaction
|
Ongoing non-discretionary purchase
of Shares matched by the grant of conditional share award over
Shares under the Diaceutics plc UK Share Incentive Plan
("SIP")
|
|
c.
|
Price(s) and volume(s)
|
|
Share purchase:
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
134 p
|
112
|
|
|
|
Matched share award:
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
Nil
|
112
|
|
|
|
|
e.
|
Date of the transaction
|
Share purchase and Matched Share
award: 30 September 2024
|
|
f.
|
Place of the transaction
|
Share Purchase: AIM Market of the
London Stock Exchange
Matched Share Award:
Off-Market
|
|
|
|
|
|
|
|
| |
|
Notification of a Transaction pursuant to Article 19(1) of
Regulation (EU) No. 596/2014
|
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a.
|
Name
|
Nick Roberts
|
|
2
|
Reason for notification
|
|
|
a.
|
Position/Status
|
Chief Finance Officer
|
|
b.
|
Initial notification/
Amendment
|
Initial
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a.
|
Name
|
Diaceutics PLC
|
|
b.
|
LEI
|
213800VEWQBB39ZB8J81
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a.
|
Description of the financial
instrument, type of instrument
Identification Code
|
Ordinary shares of
£0.002 each
ISIN:
GB00BJQTGV64
|
|
b.
|
Nature of the transaction
|
Ongoing non-discretionary purchase
of Shares matched by the grant of conditional share award over
Shares under the Diaceutics plc UK Share Incentive Plan
("SIP")
|
|
c.
|
Price(s) and volume(s)
|
|
Share purchase:
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
134 p
|
112
|
|
|
|
Matched share award:
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
Nil
|
112
|
|
|
|
|
e.
|
Date of the transaction
|
Share purchase and Matched Share
award: 30 September 2024
|
|
f.
|
Place of the transaction
|
Share Purchase: AIM Market of the
London Stock Exchange
Matched Share Award:
Off-Market
|
|
|
|
|
|
|
|
| |
|
Notification of a Transaction pursuant to Article 19(1) of
Regulation (EU) No. 596/2014
|
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a.
|
Name
|
Jillian Beggs
|
|
2
|
Reason for notification
|
|
|
a.
|
Position/Status
|
Chief Commercial Officer
|
|
b.
|
Initial notification/
Amendment
|
Initial
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a.
|
Name
|
Diaceutics PLC
|
|
b.
|
LEI
|
213800VEWQBB39ZB8J81
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a.
|
Description of the financial
instrument, type of instrument
Identification Code
|
Ordinary shares of
£0.002 each
ISIN:
GB00BJQTGV64
|
|
b.
|
Nature of the transaction
|
Ongoing non-discretionary purchase
of Shares matched by the grant of conditional share award over
Shares under the Diaceutics plc UK Share Incentive Plan
("SIP")
|
|
c.
|
Price(s) and volume(s)
|
|
Share purchase:
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
134 p
|
112
|
|
|
|
Matched share award:
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
Nil
|
112
|
|
|
|
|
e.
|
Date of the transaction
|
Share purchase and Matched Share
award: 30 September 2024
|
|
f.
|
Place of the transaction
|
Share Purchase: AIM Market of the
London Stock Exchange
Matched Share Award:
Off-Market
|
|
|
|
|
|
|
|
| |
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHQKDBKKBDBOKK
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Oct 2024 to Nov 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Nov 2023 to Nov 2024
